Search Results
Oct 14, 2025, 07:00 ET Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™
A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous (IV) Bacteriophage Cocktail (AP-SA02) vs. Placebo in Combination with Best Available Antibiotic Therapy (BAT) in Patients with Complicated Staphylococcus aureus Bacteremia
More news about: Armata Pharmaceuticals, Inc.
Oct 14, 2025, 06:00 ET Realtor.com®: Renters Now Spend Less than a Quarter of Their Income on Rent
vs. 2024)
More news about: Realtor.com
Oct 14, 2025, 04:02 ET From Silicon Valley to Mainstream Medicine: How elegant hoopoe 'Longevity Scores' Are Revolutionising Preventive Healthcare
Interview Topics: The science behind longevity scores and biological vs chronological age How AI is transforming personalised medicine Democratising elite health protocols:
More news about: elegant hoopoe
Oct 14, 2025, 03:30 ET Juniper Research & VOX Solutions Unveil Whitepaper on Reinventing A2P SMS Pricing Before It's Too Late
analytics enable real-time monitoring, competitive benchmarking, and fraud mitigation. Domestic vs International SMS - Different strategies are required: international SMS demands aggressive concessions, while domestic SMS thrives on value-driven segmentation
More news about: Vox Solutions
Oct 13, 2025, 19:30 ET LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
increase in isolated ARIA-H was observed for LEQEMBI vs placebo. Incidence of ICH ICH >1 cm in diameter was reported in 0.7% with LEQEMBI vs 0.1% with placebo. Fatal events of ICH in patients taking
More news about: Eisai Inc.
Oct 13, 2025, 13:05 ET TACHP Member Spotlight: Driscoll Health Plan's Nurture Program is Helping Pregnant Woman and Changing Lives
rates of vaginal delivery (56% vs 49.5%), a critical outcome in reducing unnecessary cesarean sections, which carry higher risks and costs. Fewer preterm births (13% vs 17%). Shorter newborn hospital stays (3.7 days vs 4.6 days).
More news about: Texas Association of Community Health Plans
Oct 13, 2025, 10:17 ET Boehringer and Click Therapeutics present pivotal data for investigational prescription digital therapeutic CT-155 showing a statistically significant reduction in negative symptoms of schizophrenia
Cohen's D effect size of -0.36 (p value= 0.0003) reflective of a 6.8-point improvement of negative symptoms severity as measured by CAINS-MAP at 16 weeks (vs. 4.2-point in digital control arm), representing a 62% relative improvement1 The majority of participants used
More news about: Boehringer Ingelheim Pharmaceuticals, Inc.; Click Therapeutics
Oct 13, 2025, 09:00 ET Revlon® Unveils New 3-In-One One-Step® Multi-Styler For Salon-Quality Hair At Home
Helen of Troy . *Versus drying and styling separately.**Based on third-party testing vs air drying in a controlled environment.
More news about: Helen of Troy
Oct 13, 2025, 08:05 ET Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics
full, and overfull viral vector capsids in less than 10 minutes per sample.2 Decreases sample volumes by 100 times vs. current methods for assessing cells and nucleic acids.3 MILFORD,
More news about: Waters Corporation
Oct 13, 2025, 08:05 ET Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics
full, and overfull viral vector capsids in less than 10 minutes per sample.2 Decreases sample volumes by 100 times vs. current methods for assessing cells and nucleic acids.3 MILFORD,
More news about: Waters Corporation
Oct 13, 2025, 08:00 ET Vasa Therapeutics Receives FDA IND Clearance to Advance Novel Small Molecule VS-041 for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)
About VS-041 VS-041 is an oral compound that was discovered and developed by Vasa for the potential treatment of HFpEF and other chronic disease characterized by fibroinflammation such as hypertrophic cardiomyopathy and chronic kidney disease. VS-041 robustly
More news about: Vasa Therapeutics
Oct 13, 2025, 07:15 ET AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
enrolled in the study, whose tumors had progressed after two lines of therapy (n=80), was done to compare the anti-cancer effect of ABBV-706 monotherapy vs. platinum-based SOC. All patients in this group had received the platinum-based SOC treatment as first-line therapy (1L SOC). Progression-free survival
More news about: AbbVie
Oct 13, 2025, 06:45 ET Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
(98% vs 84%; 2.2% vs 0%), decreased white blood cells (82% vs 27%; 13% vs 0.6%), anemia (82% vs 28%; 1.6% vs 0%), decreased neutrophil count (80% vs 21%; 21.9% vs 2.6%), decreased lymphocyte count (53% vs 26%; 7.6% vs 1.9%), decreased platelet count (36% vs 12%; 1.9% vs 0.6%), increased ALT (48% vs 25%;
More news about: Eli Lilly and Company
Oct 13, 2025, 06:16 ET GAC Launches AION V in Finland, Expanding Presence in European Electric Vehicle Market
AION V's entry into Finland is pivotal to GAC's pan-European strategy, which accelerated following the signing of a global partnership agreement with Inchcape
More news about: GAC
Oct 13, 2025, 04:24 ET Dun & Bradstreet Celebrates Marketing Excellence at the 2025 Marketing Mavericks Summit
summit featured a series of dynamic sessions including keynote speeches, panel discussions, and a compelling fireside chat titled "Building a Brand vs Building Revenue: Aligning Short-Term Wins with Long-Term Growth". Topics explored ranged from UX optimization and B2B relationship marketing
More news about: Dun & Bradstreet India
Oct 12, 2025, 20:10 ET Ascletis Selects a Best-In-Class Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for Clinical Development
-33.6% (p <0.0001 vs vehicle)
More news about: Ascletis Pharma Inc.
Oct 10, 2025, 13:35 ET ALLOSOURCE® ANNOUNCES RESEARCH FEATURING ITS PROPRIETARY VIATRUE® CRYOPRESERVATION PROCESS IS BEING PRESENTED AT THE 18TH INTERNATIONAL CARTILAGE REGENERATION & JOINT PRESERVATION SOCIETY WORLD CONGRESS
patients." The second poster, featuring research by Colorado State University in Fort Collins, Colorado titled "Cryopreservation Vs Fresh Osteochondral Allografts: Is There a Difference?" evaluates histologic and biomechanical properties of fresh versus cryopreserved OCAs (up to one
More news about: AlloSource
Oct 10, 2025, 13:08 ET LG oferece geladeiras para diferentes usos, com frescor prolongado e conectividade
reorganizou suas operações em quatro divisões de negócios:Home Appliance Solution (HS), Media Entertainment Solution (MS), Vehicle Solution (VS) e Eco Solution (ES), redefinindo seus papéis e identidades para acelerar sua visão de futuro até 2030. Em 2024, as quatro divisões combinadas
More news about: LG Electronics Brasil
Oct 10, 2025, 09:00 ET Thyme Care and American Oncology Network (AON) Present Nine Research Abstracts at ASCO Quality 2025, Showcasing Leadership in Value-Based Cancer Care Design and Delivery
Abstract #86)Evaluating the Derivation of Clinical Adjusters in the EOM: Claims Data vs. Practice-Reported Sources. Finds that HER2 status can be reliably derived from claims data, reducing reporting burden and improving accuracy. (
More news about: Thyme Care
Oct 10, 2025, 08:06 ET CHINA DRIVES STRONGEST GROWTH IN GLOBAL FACTORY PURCHASING SINCE MID-2022, WHILE NORTH AMERICAN MANUFACTURERS COOL IN SEPTEMBER: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
conditions, shortages, transportation costs, inventories, and backlogs based on a monthly survey of 27,000 businesses — was little changed in September (-0.38 vs -0.39 in August), indicating that global supply chains are operating below full capacity still.
More news about: GEP
Oct 10, 2025, 08:06 ET CHINA DRIVES STRONGEST GROWTH IN GLOBAL FACTORY PURCHASING SINCE MID-2022, WHILE NORTH AMERICAN MANUFACTURERS COOL IN SEPTEMBER: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
conditions, shortages, transportation costs, inventories, and backlogs based on a monthly survey of 27,000 businesses — was little changed in September (-0.38 vs -0.39 in August), indicating that global supply chains are operating below full capacity still.
More news about: GEP
Oct 10, 2025, 07:30 ET Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress
hepatic impairment. Adverse Reactions: The most common adverse reactions in clinical trials with CAPLYTA vs. placebo were somnolence/sedation, dizziness, nausea, and dry mouth. CAPLYTA is available in 10.5 mg, 21 mg, and 42 mg capsules.
More news about: Johnson & Johnson
Oct 09, 2025, 14:28 ET COMPLEX AND VERZUZ ANNOUNCE EXCLUSIVE PARTNERSHIP
Franklin vs. Fred Hammond; The-Dream vs. Sean Garrett; Mannie Fresh vs. Scott Storch; Boi-1da vs. Hit-Boy; Ne-Yo vs. Johntá Austin, T-Pain vs. Lil Jon; RZA vs. DJ Premiere, Erykah Badu vs. Jill Scott, Alicia Keys vs. John Legend, DMX vs. Snoop Dogg, Rick Ross vs. 2Chainz, Patti Labelle vs. Gladys Knight,
More news about: Complex
Oct 09, 2025, 12:26 ET Holiday Shoppers Split on Spending as Retailers Double Down on Incentives
divide is even more pronounced among households with children, which are gearing up to spend at nearly twice the rate of child-free households (38% vs. 19%), despite citing increased pressures on household finances from inflation and tariffs. This trend signals that shoppers with children feel more pressure
More news about: Rakuten Rewards
Oct 09, 2025, 10:41 ET FOR RESOURCEFUL GEN Z AND MILLENNIALS, WORK TRIPS ARE A LIFESTYLE UPGRADE, HOTELS.COM FINDS
experience. Compared to their older colleagues, they're more than twice as likely to pay to upgrade their flights (62% vs. 25%) or splurge on high-end dining or entertainment during a work trip (73% vs. 38). When company policy allows, the upgrades don't stop there: 26% of Gen Z would expense
More news about: Hotels.com